150 related articles for article (PubMed ID: 19323060)
21. Serum levels of metalloproteinases and their inhibitors during infection with pathogens having integrin receptor-mediated cellular entry.
Krajinović LC; Soprek S; Korva M; Dželalija B; Rode OĐ; Skerk V; Avšič-Županc T; Markotić A
Scand J Infect Dis; 2012 Sep; 44(9):663-9. PubMed ID: 22831170
[TBL] [Abstract][Full Text] [Related]
22. Is determination of matrix metalloproteinases and their tissue inhibitors serum concentrations useful in patients with gastroenteropancreatic and bronchopulmonary neuroendocrine neoplasms?
Blicharz-Dorniak J; Kos-Kudła B; Foltyn W; Kajdaniuk D; Marek B; Zemczak A; Strzelczyk J
Endokrynol Pol; 2012; 63(6):470-6. PubMed ID: 23339005
[TBL] [Abstract][Full Text] [Related]
23. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer.
Hilska M; Roberts PJ; Collan YU; Laine VJ; Kössi J; Hirsimäki P; Rahkonen O; Laato M
Int J Cancer; 2007 Aug; 121(4):714-23. PubMed ID: 17455256
[TBL] [Abstract][Full Text] [Related]
25. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients.
Giannelli G; Erriquez R; Fransvea E; Daniele A; Trerotoli P; Schittulli F; Grano M; Quaranta M; Antonaci S
Int J Cancer; 2004 May; 109(5):782-5. PubMed ID: 14999790
[TBL] [Abstract][Full Text] [Related]
26. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
Ulrich D; Hrynyschyn K; Pallua N
Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
[TBL] [Abstract][Full Text] [Related]
27. Plasma Levels and Tissue Expression of Selected Cytokines, Metalloproteinases and Tissue Inhibitors in Patients With Cervical Cancer.
Sidorkiewicz I; Piskór B; Dąbrowska E; Guzińska-Ustymowicz K; Pryczynicz A; Zbucka-Krętowska M; Ławicki S
Anticancer Res; 2019 Nov; 39(11):6403-6412. PubMed ID: 31704874
[TBL] [Abstract][Full Text] [Related]
28. Dysregulation of the levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the early phase of cerebral ischemia.
Lorenzl S; De Pasquale G; Segal AZ; Beal MF
Stroke; 2003 Jun; 34(6):e37-8; author reply e37-8. PubMed ID: 12750528
[No Abstract] [Full Text] [Related]
29. Concentration of metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in the serum of patients with benign and malignant thyroid tumours treated surgically.
Pasieka Z; Stepien H; Czyz W; Pomorski L; Kuzdak K
Endocr Regul; 2004 Jun; 38(2):57-63. PubMed ID: 15497929
[TBL] [Abstract][Full Text] [Related]
30. Systemic regulation of angiogenesis and matrix degradation in bone regeneration--distraction osteogenesis compared to rigid fracture healing.
Weiss S; Zimmermann G; Baumgart R; Kasten P; Bidlingmaier M; Henle P
Bone; 2005 Dec; 37(6):781-90. PubMed ID: 16202678
[TBL] [Abstract][Full Text] [Related]
31. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
[TBL] [Abstract][Full Text] [Related]
32. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure.
Altieri P; Brunelli C; Garibaldi S; Nicolino A; Ubaldi S; Spallarossa P; Olivotti L; Rossettin P; Barsotti A; Ghigliotti G
Eur J Clin Invest; 2003 Aug; 33(8):648-56. PubMed ID: 12864774
[TBL] [Abstract][Full Text] [Related]
33. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies.
Horstmann S; Kalb P; Koziol J; Gardner H; Wagner S
Stroke; 2003 Sep; 34(9):2165-70. PubMed ID: 12907822
[TBL] [Abstract][Full Text] [Related]
34. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms.
Furuya M; Ishikura H; Kawarada Y; Ogawa Y; Sakuragi N; Fujimoto S; Yoshiki T
Gynecol Oncol; 2000 Aug; 78(2):106-12. PubMed ID: 10926788
[TBL] [Abstract][Full Text] [Related]
35. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
36. Reduced levels of MMP-2 and TIMP-1 in dyssegmental dysplasia.
Uchide K; Ueno H; Takizawa N; Okada Y
J Bone Miner Res; 2003 Feb; 18(2):381-2. PubMed ID: 12568417
[TBL] [Abstract][Full Text] [Related]
37. The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome.
Erman H; Gelisgen R; Cengiz M; Tabak O; Erdenen F; Uzun H
Eur Rev Med Pharmacol Sci; 2016; 20(6):1015-22. PubMed ID: 27049251
[TBL] [Abstract][Full Text] [Related]
38. MMP, VEGF and TIMP as prognostic factors in recurring bladder cancer.
Wieczorek E; Jablonowski Z; Tomasik B; Konecki T; Jablonska E; Gromadzinska J; Fendler W; Sosnowski M; Wasowicz W; Reszka E
Clin Biochem; 2015 Dec; 48(18):1235-40. PubMed ID: 26197083
[TBL] [Abstract][Full Text] [Related]
39. Changes of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in the serum of patients with autoimmune diseases: association with age and disease activity.
Ziouti N; Vynios DH; Aletras AJ; Kyriakopoulou D; Mastorakou A; Andonopoulos A
Clin Chem Lab Med; 2004; 42(8):880-8. PubMed ID: 15387437
[TBL] [Abstract][Full Text] [Related]
40. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis.
Mühl D; Nagy B; Woth G; Falusi B; Bogár L; Weber G; Lantos J
J Crit Care; 2011 Dec; 26(6):550-5. PubMed ID: 21530151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
